Magenta Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Dianthus Therapeutics

31/10/2022 11:47

* Magenta Therapeutics Inc  MGTA.OQ   MGTA.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Magenta
Therapeutics Inc
is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Magenta
Therapeutics Inc is $6​, above​ its last closing price of $1.25.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.35       -0.33      -0.29     Beat    12.1
 Mar. 31 2022  -0.33       -0.31      -0.39     Missed  -24.7
 Dec. 31 2021  -0.32       -0.32      -0.33     Missed  -2.6​
 Sep. 30 2021  -0.32       -0.33      -0.30     Beat    8.6
 ​​Jun.        -0.37       -0.38      -0.32     Beat    15.3
 30 2021                                                
 Mar. 31 2021  -0.40       -0.40      -0.36     Beat    10.4​
 Dec. 31 2020  -0.41       -0.42      -0.38     Beat    8.5
 Sep. 30 2020  -0.45       -0.45      -0.37     Beat    17.5
 This summary was machine generated October 31 at 11:47 GMT.  All
figures in US dollars  unless otherwise stated